Literature DB >> 15864651

Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine.

Jens Graupner1, Klaus Göbels, Martin P Grobusch, Anne Lund, Joachim Richter, Dieter Häussinger.   

Abstract

Falciparum Malaria is hyperendemic in southern Nigeria and chloroquine resistance is an increasing problem. Therefore, the parasitological and haematological response to treatment with amodiaquine was studied in children under 5 years during a 14-day follow-up. Of 105 children who accomplished the study (out of 114 who were enrolled), 95.3% were parasite-negative on thick blood film on day 7, which decreased to 89.5% on day 14. The haemoglobin levels increased on average by 1.3% on day 14 (+/-1.9) and more pronounced in children with anaemia<10 g/dl on enrollment. The number of patients with adverse events (mainly pruritus and nausea) was few. This study shows that amodiaquine is effective, safe and affordable in an area with high resistance to chloroquine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864651     DOI: 10.1007/s00436-005-1325-7

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  15 in total

1.  A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya.

Authors:  J van Dillen; M Custers; A Wensink; B Wouters; T van Voorthuizen; W Voorn; B Khan; L Muller; C Nevill
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Mar-Apr       Impact factor: 2.184

2.  Chloroquine-resistant Plasmodium falciparum among children in Calabar, south eastern Nigeria.

Authors:  O E Antia-Obong; A A Alaribe; M U Young; A Bassy; B V Etim
Journal:  Trop Doct       Date:  1997-07       Impact factor: 0.731

3.  Amodiaquine as the first-line treatment of malaria in Yaoundé, Cameroon: presumptive evidence from activity in vitro and cross-resistance patterns.

Authors:  P Ringwald; J Bickii; L K Basco
Journal:  Trans R Soc Trop Med Hyg       Date:  1998 Mar-Apr       Impact factor: 2.184

4.  [Evaluation of efficacy and tolerance of amodiaquine versus chloroquine in the treatment of uncomplicated malaria outbreak in children of Gabon].

Authors:  V Guiyedi; J Koko; M Bouyou Akotet; M Mabika Manfoumbi; P B Matsiégui; B Traoré; M Kombila
Journal:  Bull Soc Pathol Exot       Date:  2001-08

Review 5.  Systematic review of amodiaquine treatment in uncomplicated malaria.

Authors:  P Olliaro; C Nevill; J LeBras; P Ringwald; P Mussano; P Garner; P Brasseur
Journal:  Lancet       Date:  1996-11-02       Impact factor: 79.321

6.  Evaluation of the relative efficacy of various antimalarial drugs in Nigerian children under five years of age suffering from acute uncomplicated falciparum malaria.

Authors:  A Sowunmi; L A Salako
Journal:  Ann Trop Med Parasitol       Date:  1992-02

Review 7.  The public health impact of chloroquine resistance in Africa.

Authors:  J F Trape
Journal:  Am J Trop Med Hyg       Date:  2001 Jan-Feb       Impact factor: 2.345

8.  Using evidence to change antimalarial drug policy in Kenya.

Authors:  R Shretta; J Omumbo; B Rapuoda; R W Snow
Journal:  Trop Med Int Health       Date:  2000-11       Impact factor: 2.622

9.  Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis.

Authors:  P Sudre; J G Breman; D McFarland; J P Koplan
Journal:  Int J Epidemiol       Date:  1992-02       Impact factor: 7.196

10.  In vivo efficacy of chloroquine, halofantrine, pyrimethamine-sulfadoxine and qinghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria.

Authors:  E Ezedinachi
Journal:  Cent Afr J Med       Date:  1996-04
View more
  1 in total

1.  Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine-amodiaquine failure in Pikine, Senegal.

Authors:  Ousmane Sarr; Ambroise D Ahouidi; Omar Ly; Johanna P Daily; Daouda Ndiaye; Omar Ndir; Souleymane Mboup; Dyann F Wirth
Journal:  Parasitol Res       Date:  2008-06-05       Impact factor: 2.289

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.